Recombinant NDV LX/IL (15 + 7), which co-expresses IL-7 and IL-15, enhanced the infiltration of CD8+ and CD4+ T cells, significantly inhibiting tumor growth in melanoma (59). Here, CD8A is linked to melanoma.